{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:01:21Z","timestamp":1761512481718},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1016\/j.lungcan.2007.10.019","type":"journal-article","created":{"date-parts":[[2007,12,6]],"date-time":"2007-12-06T17:06:25Z","timestamp":1196960785000},"page":"374-380","source":"Crossref","is-referenced-by-count":20,"title":["Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer"],"prefix":"10.1016","volume":"60","author":[{"given":"Christian","family":"Peschel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joerg T.","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Schmittel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten","family":"Bokemeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Folker","family":"Schneller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Keilholz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dieter","family":"Buchheidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Millan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel \u00c1ngel","family":"Izquierdo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf-Dieter","family":"Hofheinz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2007.10.019_bib1","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1200\/JCO.2004.09.053","article-title":"American society of clinical oncology: treatment of unresectable non-small cell lung cancer guideline: update 2003","volume":"22","author":"Pfister","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2007.10.019_bib2","series-title":"AJCC cancer staging manual","article-title":"American Joint Committee on Cancer","author":"Lung","year":"2002"},{"key":"10.1016\/j.lungcan.2007.10.019_bib3","first-page":"2347","article-title":"The role of new agents in the treatment of non-small cell lung cancer","volume":"38","author":"Broker","year":"2002","journal-title":"Eur J Cancer Clin Oncol"},{"key":"10.1016\/j.lungcan.2007.10.019_bib4","first-page":"626","article-title":"Advanced non-small-cell lung cancer: new data, therapy choices, and challenging decisions","volume":"20","author":"Sandler","year":"2006","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.lungcan.2007.10.019_bib5","doi-asserted-by":"crossref","first-page":"7533","DOI":"10.1038\/sj.onc.1205972","article-title":"Aplidin induces the mitochondrial apoptotic pathway via oxidative stress-mediated JNK and p38 activation and protein kinase C delta","volume":"21","author":"Garcia-Fernandez","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.lungcan.2007.10.019_bib6","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1124\/mol.106.025569","article-title":"Plitidepsin cellular binding and Rac1\/JNK pathway activation depend on membrane cholesterol content","volume":"70","author":"Suarez","year":"2006","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.lungcan.2007.10.019_bib7","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1038\/sj.onc.1207636","article-title":"JNK activation is critical for aplidin-induced apoptosis","volume":"23","author":"Cuadrado","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.lungcan.2007.10.019_bib8","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1074\/jbc.M201010200","article-title":"Aplidin induces apoptosis in human cancer cells via glutathione depletion and sustained activation of the epidermal growth factor receptor, Src, JNK, and p38 MAPK","volume":"278","author":"Cuadrado","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.lungcan.2007.10.019_bib9","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1038\/sj.cdd.4401898","article-title":"Aplidin induces JNK-dependent apoptosis in human breast cancer cells via alteration of glutathione homeostasis, Rac1 GTPase activation, and MKP-1 phosphatase downregulation","volume":"13","author":"Gonzalez-Santiago","year":"2006","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.lungcan.2007.10.019_bib10","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/sj.leu.2402788","article-title":"Aplidine a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4","volume":"17","author":"Broggini","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.lungcan.2007.10.019_bib11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00280-005-0014-7","article-title":"Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes","volume":"57","author":"Straight","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.lungcan.2007.10.019_bib12","series-title":"Proceedings of the American Society of Clinical Oncology","article-title":"Phase I and pharmacokinetic (PK) study of aplidin (APL) using a 24-hour, weekly schedule","author":"Anthoney","year":"2000"},{"key":"10.1016\/j.lungcan.2007.10.019_bib13","series-title":"Proceedings of the American Society of Clinical Oncology","article-title":"Phase I clinical and pharmacokinetic (PK) study of the marine compound aplidin (APL), administered as a 1-h weekly infusion","author":"Bowman","year":"2001"},{"key":"10.1016\/j.lungcan.2007.10.019_bib14","doi-asserted-by":"crossref","first-page":"7871","DOI":"10.1200\/JCO.2005.09.357","article-title":"Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies","volume":"23","author":"Faivre","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2007.10.019_bib15","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/00001813-200404000-00003","article-title":"Progress in the clinical development of new marine-derived anticancer compounds","volume":"15","author":"Jimeno","year":"2004","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.lungcan.2007.10.019_bib16","series-title":"Proceedings of the American Society of Clinical Oncology","article-title":"Phase I clinical and pharmacokinetic study of the marine compound aplidin (APL) administered as a 3-h infusion every 2 weeks","author":"Ciruelos","year":"2002"},{"key":"10.1016\/j.lungcan.2007.10.019_bib17","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/annonc\/mdl165","article-title":"Phase I study of aplidine in a daily\u00d75 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy","volume":"17","author":"Maroun","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lungcan.2007.10.019_bib18","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1200\/JCO.2000.18.20.3558","article-title":"Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines","volume":"18","author":"Ozer","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2007.10.019_bib19","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1200\/JCO.1999.17.9.2971","article-title":"Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines","volume":"17","author":"Gralla","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2007.10.019_bib20","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.lungcan.2007.10.019_bib21","unstructured":"National Cancer Institute Common Toxicity Criteria. Version 2.0, June 1, 1999. Available at: http:\/\/ctep.info.nih.gov. Accessed January 20, 2005."},{"key":"10.1016\/j.lungcan.2007.10.019_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.lungcan.2007.10.019_bib23","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy","volume":"22","author":"Hanna","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2007.10.019_bib24","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1200\/JCO.2000.18.10.2095","article-title":"Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy","volume":"18","author":"Shepherd","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2007.10.019_bib25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0169-5002(02)00167-8","article-title":"Second line chemotherapy for NSCLC: establishing a gold standard","volume":"38","author":"Fossella","year":"2002","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2007.10.019_bib26","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1200\/JCO.2003.01.144","article-title":"Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response","volume":"21","author":"Erasmus","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2007.10.019_bib27","first-page":"543","article-title":"Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas","volume":"38","author":"Van Glabbeke","year":"2002","journal-title":"Eur J Cancer Clin Oncol"},{"key":"10.1016\/j.lungcan.2007.10.019_bib28","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0140-6736(04)17098-0","article-title":"Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial","volume":"364","author":"Verweij","year":"2004","journal-title":"Lancet"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500207006253?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500207006253?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,5]],"date-time":"2019-05-05T17:05:49Z","timestamp":1557075949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500207006253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["S0169500207006253"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2007.10.019","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}